New hope for relapsed lung cancer: drug cocktail trial launches
NCT ID NCT05568212
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help people with stage III non-small-cell lung cancer whose disease has returned after initial treatment. It also explores adding the targeted drug olaparib to durvalumab for certain patients. The study involves 176 participants and aims to see if these combinations improve survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- durvalumab, olaparib, and chemotherapy
- What this could lead to
- If successful, this could offer new treatment options for people with advanced lung cancer whose disease has returned after initial therapy.
- What could go wrong
- This is an early phase 2 trial with only 176 participants, so results may not apply to everyone. Drug combinations can also cause more side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER PATIENTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Istituti Fisioterapici Ospitalieri- Ifo - Istituto Regina Elena
RECRUITINGRoma, RM, 00144, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.